Across TCGA pan-cancer cohorts, FAM230F RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of FAM230F’s most consistent transcriptional readouts.
The strongest signal is observed in thyroid carcinoma (THCA), where FAM230F RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FAM230F is over-expressed in tumor.
THCA are the cancer types where FAM230F tumor–normal differential expression is most reproducible.